Flora Growth (FLGC, $0.26) has a new growth opportunity via Franchise Global Health acquisition
Flora Growth Corp. is beginning 2023 with a major acquisition. As 2022 ended, Flora completed the acquisition of Franchise Global Health. Franchise Global Health is a Canadian cannabis company with primary operations in Germany, and is the owner of the first German medical cannabis import and distribution license.
This acquisition potentially boosts Flora’s access to Germany’s cannabis market and over 1,200 pharmacies. Some estimate suggests that the German medical cannabis market will surpass $900 million by 2025. Even Franchise Global Health could possibly benefit from the deal, in its ability to meet growing demand. Franchise Global Health’s suppliers were only able to deliver around 4 kilos every 8 weeks when the company had a demand of over 100 kilos every month.
FLGC's RSI Indicator climbs out of oversold territory
The RSI Oscillator for FLGC moved out of oversold territory on August 08, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 11, 2025. You may want to consider a long position or call options on FLGC as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for FLGC just turned positive on August 14, 2025. Looking at past instances where FLGC's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
FLGC moved above its 50-day moving average on September 11, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGC advanced for three days, in of 171 cases, the price rose further within the following month. The odds of a continued upward trend are .
FLGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for FLGC entered a downward trend on August 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.488) is normal, around the industry mean (17.281). P/E Ratio (0.000) is within average values for comparable stocks, (74.632). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). FLGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.203) is also within normal values, averaging (46.794).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FLGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement